# PCV13 + Hepatitis A Vaccine for Adults

> **NCT01926860** · PHASE4 · COMPLETED · sponsor: **Helsinki University Central Hospital** · enrollment: 305 (actual)

## Conditions studied

- Measurement of Immune Response to Prevenar13
- Measurement of Immune Response to Hepatitis A

## Interventions

- **BIOLOGICAL:** Prevenar13
- **BIOLOGICAL:** Hepatitis A vaccine

## Key facts

- **NCT ID:** NCT01926860
- **Lead sponsor:** Helsinki University Central Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08-24
- **Primary completion:** 2019-10-28
- **Final completion:** 2020-04-28
- **Target enrollment:** 305 (ACTUAL)
- **Last updated:** 2024-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01926860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01926860, "PCV13 + Hepatitis A Vaccine for Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01926860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*